LMND vs HIPO vs ROOT vs OSCR vs CLOV

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 25. 9% for Hippo Holdings Inc. (HIPO). Hippo Holdings Inc. (HIPO) offers the better valuation at 12. 4x trailing P/E (114. 3x forward), making it the more compelling value choice. Analysts rate Lemonade, Inc. (LMND) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hippo Holdings Inc.

(HIPO) is the cheapest at 12. 4x versus Root, Inc. at 25. 4x. On forward P/E, Root, Inc. is actually cheaper at 29. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Oscar Health, Inc.

(OSCR) delivered a total return of -7. 3%, compared to -88. 9% for Hippo Holdings Inc. (HIPO). Over 10 years, the gap is even starker: LMND returned -21. 6% versus HIPO's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Clover Health Investments, Corp.

(CLOV) is the lower-risk stock at 1. 22β versus Lemonade, Inc. 's 2. 75β — meaning LMND is approximately 126% more volatile than CLOV relative to the S&P 500. On balance sheet safety, Hippo Holdings Inc. (HIPO) carries a lower debt/equity ratio of 12% versus 51% for Root, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus 25. 9% for Hippo Holdings Inc. (HIPO). On earnings-per-share growth, the picture is similar: Hippo Holdings Inc. grew EPS 235. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, ROOT leads at 69. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hippo Holdings Inc.

(HIPO) is the more profitable company, earning 12. 3% net margin versus -22. 4% for Lemonade, Inc. — meaning it keeps 12. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIPO leads at 13. 5% versus -21. 8% for LMND. At the gross margin level — before operating expenses — HIPO leads at 50. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Root, Inc.

(ROOT) trades at 29. 0x forward P/E versus 114. 3x for Hippo Holdings Inc. — 85. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LMND: 33. 5% to $72. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Clover Health Investments, Corp.

(CLOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Root, Inc. (ROOT) carries a higher beta of 2. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLOV: -72. 4%, ROOT: -88. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LMND (Financial Services) and HIPO (Financial Services) and ROOT (Financial Services) and OSCR (Healthcare) and CLOV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.